Event date: true event date is unknown.Event date is estimated to the first month of the clinical study (b)(6) 2016.Implant date: between (b)(6) 2016 - (b)(6) 2017.Apa citation: lakhoo, j., adams, r., dave, a., luo, l., vargo, c.J., isaacson, a.J., sher, a., fischman, a., yee, d.C., ryan, s., patel, s., duchac, d., & brown, d.B.(2020).Radiopaque beads loaded with doxorubicin in the treatment of patients with hepatocellular carcinoma: a retrospective, multi-center study.Cancer treatment and research communications, 25, 100208.Https://doi.Org/10.1016/j.Ctarc.2020.100208.
|
It was reported via a retrospective, multi-center study "radiopaque beads loaded with doxorubicin in the treatment of patients with hepatocellular carcinoma" that patients experienced fatigue, abdominal pain and toxicity.The primary objective of this study was to evaluate overall disease and target tumor response of non-resectable hepatocellular carcinoma (hcc) after transarterial chemoembolization (tace) with a doxorubicin-loaded radiopaque microsphere.Data as abstracted from records of patients with unresectable hcc who received tace with doxorubicin loaded radiopaque lc bead lumi microspheres at one of five united states centers between february 2016 - november 2017.82 patients underwent 130 treatments.Most patients, however, received only one (45/82) or two treatments (29/82).Five patients experienced adverse events of fatigue, abdominal pain and toxicity.No grade 4-5 toxicities occurred.No treatment information was supplied in the article.
|